Ardelyx, Inc. filings document a commercial-stage biopharmaceutical company with U.S. product revenue from IBSRELA and XPHOZAH and development activity centered on tenapanor and NHE3 inhibition. Form 8-K reports cover quarterly operating results, preliminary product sales, cash and investment updates, Regulation FD presentation materials, and other material-event disclosures tied to the company’s commercial and clinical programs.
Ardelyx proxy materials describe annual meeting proposals, director elections, say-on-pay matters, auditor ratification, executive compensation, board structure, and stockholder voting mechanics. Additional current reports record officer appointments, executive transitions, transition and separation agreements, compensatory arrangements, governance matters, and disclosure controls relevant to the company’s public-company reporting obligations.
Ardelyx, Inc. chief financial officer Susan Hohenleitner reported equity awards consisting of common stock and stock options. On January 23, 2026, she received 85,670 shares of common stock at a price of $0, described as restricted stock units that convert into one share of common stock per unit upon vesting. Following this grant, she beneficially owned 232,566 shares of Ardelyx common stock directly.
On the same date, she was also granted a stock option for 128,505 shares with an exercise price of $7.77 per share and an expiration date of January 23, 2036. The option becomes exercisable as it vests in 48 equal monthly installments starting on January 23, 2026, conditioned on her continued employment or service with Ardelyx.
Ardelyx, Inc. Chief Commercial Officer Eric Duane Foster reported new equity awards and updated his share holdings. On January 23, 2026, he received 137,945 shares of Common Stock for no cash consideration in the form of restricted stock units, each RSU converting into one share upon vesting. Following this grant, he beneficially owned 436,409 shares of Common Stock, which include 2,780 shares previously purchased under the Ardelyx Employee Stock Purchase Plan on August 31, 2025. He was also granted a stock option for 206,915 shares of Common Stock with a $7.77 exercise price, vesting in 48 equal monthly installments beginning on January 23, 2026, contingent on his continued employment.
Ardelyx, Inc. President and CEO Michael Raab reported new equity awards in the form of restricted stock units and stock options. On January 23, 2026, he received 446,220 RSUs at a price of $0, each RSU convertible into one share of common stock upon vesting. On the same date, he was granted a stock option for 669,330 shares of common stock at an exercise price of $7.77 per share, which vests in 48 equal monthly installments starting January 23, 2026, subject to continued service. Following these grants, Raab directly holds 1,902,968 shares of Ardelyx common stock, with additional indirect holdings of 24,364 shares and 1,000 shares through family trusts.
Ardelyx, Inc. reported an equity compensation grant to its Chief Human Resources Officer effective January 23, 2026. The officer received 99,455 restricted stock units (RSUs), with each RSU settling into one share of common stock upon vesting, increasing the officer’s directly held common stock to 265,455 shares. On the same date, the officer was also granted a stock option for 149,185 shares of common stock at an exercise price of $7.77 per share. The option vests in 48 equal monthly installments starting from January 23, 2026, conditioned on continued employment or service, and will remain exercisable until January 23, 2036.
Ardelyx Chief Patient Officer receives new equity awards. Laura A. Williams reported a grant of 82,695 shares of Ardelyx common stock on January 23, 2026, issued at $0 per share as restricted stock units that convert 1-for-1 into common stock when they vest. She also received a stock option for 124,040 shares of common stock at an exercise price of $7.77 per share, granted at no cost. The option vests in 48 equal monthly installments starting January 23, 2026, conditioned on her continued employment or service. Following these transactions, Williams directly beneficially owned 444,258 shares of Ardelyx common stock.
Ardelyx, Inc. reported an equity award to executive John E. Bishop, its Chief Technical and Quality Officer. On January 23, 2026, he received 124,330 shares of Common Stock in the form of restricted stock units, at a price of $0 per share, bringing his directly held Common Stock to 342,330 shares after the grant. He was also granted a stock option for 186,500 shares of Common Stock with an exercise price of $7.77 per share. The option vests in 48 equal monthly installments beginning on January 23, 2026, subject to his continued employment or service, and is exercisable through January 23, 2036.
Ardelyx, Inc. received a Schedule 13G filing from hedge fund–related entities reporting significant passive ownership of its common stock. Integrated Core Strategies (US) LLC reports beneficial ownership of 12,855,317 shares, representing 5.3% of the common stock. Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 13,121,781 shares, or 5.4% of the class, with shared voting and dispositive power and no sole authority. The filing states that the securities were not acquired and are not held for the purpose of changing or influencing control of Ardelyx, but instead are held on a passive basis.
Ardelyx, Inc. Chief Patient Officer Laura A. Williams reported an option exercise and share sale in Ardelyx common stock. On January 8, 2026, she exercised stock options to acquire 50,000 shares of common stock at an exercise price of $0.99 per share, then sold 50,000 shares at a weighted average price of $6.978 per share, with individual trades executed between $6.97 and $7.00.
After these transactions, Williams directly owned 361,563 shares of Ardelyx common stock, a figure that reflects an earlier purchase of 1,667 shares under the Ardelyx Employee Stock Purchase Plan in August 2025. She also held 62,000 stock options with a $0.99 exercise price, expiring on January 6, 2032, which vest in equal monthly installments that began in January 2022.
Ardelyx stockholder plans to sell shares under Rule 144. A notice was filed for the planned sale of 50,000 shares of Ardelyx common stock through Morgan Stanley Smith Barney LLC on or around 01/08/2026, listed with an aggregate market value of $291,500. The shares are to be sold on the NASDAQ, and the filing shows total Ardelyx shares outstanding of 242,974,306.
The 50,000 shares were acquired the same day, 01/08/2026, via a cash exercise of stock options granted by the issuer. The filing also reports that Laura A. Williams sold 6,426 Ardelyx common shares in a prior transaction on 11/21/2025 for gross proceeds of $35,580.12. By signing the notice, the seller represents they are not aware of undisclosed material adverse information about the company.
Ardelyx, Inc. reported preliminary, unaudited product sales for 2025. U.S. net product sales revenue of IBSRELA® (tenapanor) was approximately $87 million in the fourth quarter and approximately $274 million for the full year ended December 31, 2025. U.S. net product sales revenue of XPHOZAH® (tenapanor) was approximately $28 million in the fourth quarter and approximately $104 million for the full year.
The company also indicated it had approximately $265 million in cash, cash equivalents, and short-term investments as of December 31, 2025, on an unaudited basis. All figures are preliminary, may be adjusted during the audit process, and have not been audited or reviewed by Ernst & Young LLP.